{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:30:16Z","timestamp":1792121416063,"version":"4.4.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The prognostic significance of Treg and Th17 cells, as well as their ratio (Th17\/Treg), in cervical cancer remains a topic of debate. Our study aimed to clarify their association with patient survival and clinical outcomes in cervical cancer through a comprehensive meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>We conducted a comprehensive search in PubMed, Embase, and Web of Science to identify eligible studies. Studies related to cervical cancer and involving Treg cells or Th17 cells were included. For prognostic analysis, we collected Hazard Ratio values of patient survival. For studies focusing on clinical characteristics, we selected mean and standard deviation values for further analysis. This study was registered at PROSPERO (ID:CRD42024546507).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of the 2949 records initially retrieved, we ultimately included 21 studies in our analysis. High levels of Treg cells were found to be correlated with shorter survival in patients with cervical cancer. Subgroup analysis revealed that the prognostic effect of Treg cells on cervical cancer was not influenced by their source or definition. However, analyses of different survival measures indicated that only Overall Survival showed a correlation with Treg cell levels. Additionally, Treg cells were associated with clinical staging. High-grade Th17 cells were associated with lymphatic metastases and advanced clinical stage. The Th17\/Treg ratio was found to be elevated in both cervical intraepithelial neoplasia and cervical cancer patients compared to controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Despite limitations such as heterogeneity among selected studies and inadequate subgroup analyses, our study contributes to a deeper understanding of the significance of Treg cells in the onset and progression of cervical cancer. It also provides valuable insights for future research in immunotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier CRD42024546507.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1442103","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T04:10:24Z","timestamp":1726027824000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["The prognostic value of Th17\/Treg cell in cervical cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Jingwei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijie","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziting","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis","volume":"8","author":"Arbyn","year":"2019","journal-title":"Lancet Glob Health"},{"key":"B2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.36129\/jog.2024.161","article-title":"State of the art on HPV-related cervical lesions","volume":"36","author":"Golia D\u2019Aug\u00e8","year":"2024","journal-title":"Ital J Gynaecol Obstet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070115","article-title":"Human papillomavirus vaccination and cervical cancer risk","volume":"379","author":"Rahangdale","year":"2022","journal-title":"BMJ"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.10.004","article-title":"APOBEC: A molecular driver in cervical cancer pathogenesis","volume":"496","author":"Revathidevi","year":"2021","journal-title":"Cancer Lett"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2833","article-title":"Cervical cancer immunotherapy: Facts and hopes","volume":"27","author":"Ferrall","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/03008916231208344","article-title":"HPV-related lesions after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer: A focus on the potential role of vaccination","volume":"110","author":"Bogani","year":"2023","journal-title":"Tumori J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12486","article-title":"Interactions of Indoleamine 2,3-dioxygenase-expressing LAMP3+ dendritic cells with CD4+ regulatory T cells and CD8+ exhausted T cells: synergistically remodeling of the immunosuppressive microenvironment in cervical cancer and therapeutic implications","volume":"43","author":"Qu","year":"2023","journal-title":"Cancer Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-100219-020937","article-title":"Regulatory T cell development","volume":"38","author":"Savage","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2011.07.005","article-title":"Tumor-infiltrating lymphocytes contain a higher proportion of FOXP3(+) T lymphocytes in cervical cancer","volume":"110","author":"Wu","year":"2011","journal-title":"J Formos Med Assoc"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.07.006","article-title":"Prognostic and therapeutic TILs of cervical cancer\u2014current advances and future perspectives","volume":"22","author":"Tang","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nri2742","article-title":"TH17 cells in tumour immunity and immunotherapy","volume":"10","author":"Zou","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-208249","article-title":"Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments","volume":"114","author":"Kryczek","year":"2009","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0732","article-title":"Stromal Fibroblasts Induce CCL20 through IL6\/C\/EBP\u03b2 to Support the Recruitment of Th17 Cells during Cervical Cancer Progression","volume":"75","author":"Walch-R\u00fcckheim","year":"2015","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1913","article-title":"Cervical cancer-instructed stromal fibroblasts enhance IL23 expression in dendritic cells to support expansion of th17 cells","volume":"79","author":"Walch-R\u00fcckheim","year":"2019","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13095","article-title":"Chemoradiotherapy-induced increase in Th17 cell frequency in cervical cancer patients is associated with therapy resistance and early relapse","volume":"15","author":"Theobald","year":"2021","journal-title":"Mol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-018-0004-4","article-title":"When worlds collide: Th17 and treg cells in cancer and autoimmunity","volume":"15","author":"Knochelmann","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.immuni.2008.05.007","article-title":"Molecular antagonism and plasticity of regulatory and inflammatory T cell programs","volume":"29","author":"Yang","year":"2008","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14649","article-title":"Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ treg cells are a source of tumour-associated treg cells","volume":"8","author":"Downs-Canner","year":"2017","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12943-016-0551-1","article-title":"Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis","volume":"15","author":"Marshall","year":"2016","journal-title":"Mol Cancer"},{"key":"B21","article-title":"Imbalance of th1\/th2 and th17\/treg during the development of uterine cervical cancer","volume":"12","author":"Lin","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-001135","article-title":"CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study","volume":"30","author":"Mayadev","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e30","article-title":"Recent breakthroughs in the management of locally advanced and recurrent\/metastatic cervical cancer","volume":"35","author":"Garc\u00eda","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"B25","unstructured":""},{"key":"B26","unstructured":"Appendix D. Quality assessment forms\n          \n          \n            \n              Rostom\n              A\n            \n            \n              Dub\u00e9\n              C\n            \n            \n              Cranney\n              A\n            \n            \n              Saloojee\n              N\n            \n            \n              Sy\n              R\n            \n            \n              Garritty\n              C\n            \n          \n          Agency for Healthcare Research and Quality (US\n          Celiac Disease\n          \n          2004"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4554","article-title":"Human leukocyte antigen class I, MHC class I chain-related molecule a, and CD8+\/regulatory T-cell ratio: Which variable determines survival of cervical cancer patients","volume":"14","author":"Jordanova","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/cmi.2010.56","article-title":"A reversed CD4\/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix","volume":"8","author":"Shah","year":"2011","journal-title":"Cell Mol Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12967-015-0664-0","article-title":"The tumor area occupied by tbet+ cells in deeply invading cervical cancer predicts clinical outcome","volume":"13","author":"Gorter","year":"2015","journal-title":"J Transl Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/ijc.32782","article-title":"Highly immunosuppressive HLADRhi regulatory T cells are associated with unfavorable outcomes in cervical squamous cell carcinoma","volume":"146","author":"Yang","year":"2020","journal-title":"Int J Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33411","article-title":"The combined action of monocytic myeloid-derived suppressor cells and mucosal-associated invariant T cells promotes the progression of cervical cancer","volume":"148","author":"Lu","year":"2021","journal-title":"Int J Cancer"},{"key":"B33","article-title":"Expression and clinicopathological significance of foxp3 and VISTA in cervical cancer","volume":"13","author":"Li","year":"2021","journal-title":"Am J Transl Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.858164","article-title":"PD-1\/PD-l1 correlates with the efficacy of the treatment of concurrent chemoradiotherapy in cervical cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e005151","DOI":"10.1136\/jitc-2022-005151","article-title":"T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer","volume":"10","author":"Ni","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2023.2290909","article-title":"IL-10+CD19+ regulatory B cells induce CD4+foxp3+regulatory T cells in serum of cervical cancer patients","volume":"57","author":"Yang","year":"2024","journal-title":"Autoimmunity"},{"key":"B37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1600-0897.2008.00590.x","article-title":"Regulatory T cells in a spectrum of HPV-induced cervical lesions: Cervicitis, cervical intraepithelial neoplasia and squamous cell carcinoma","volume":"60","author":"Adurthi","year":"2008","journal-title":"Am J Reprod Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cca.2011.01.015","article-title":"The imbalance of th17\/treg in patients with uterine cervical cancer","volume":"412","author":"Zhang","year":"2011","journal-title":"Clin Chim Acta"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2012.07.012","article-title":"Distribution of th17 cells and foxp3-expressing T cells in tumor-infiltrating lymphocytes in patients with uterine cervical cancer","volume":"413","author":"Hou","year":"2012","journal-title":"Clin Chim Acta"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-8-61","article-title":"The th17\/treg balance and the expression of related cytokines in uygur cervical cancer patients","volume":"8","author":"Chen","year":"2013","journal-title":"Diagn Pathol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1186\/s12885-015-1767-y","article-title":"The existence of th22, pure th17 and th1 cells in CIN and cervical cancer along with their frequency variation in different stages of cervical cancer","volume":"15","author":"Zhang","year":"2015","journal-title":"BMC Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0120855","DOI":"10.1371\/journal.pone.0120855","article-title":"Preferential recruitment of th17 cells to cervical cancer via CCR6-CCL20 pathway","volume":"10","author":"Yu","year":"2015","journal-title":"PloS One"},{"key":"B43","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cam4.1279","article-title":"Effects of th17 cells and IL-17 in the progression of cervical carcinogenesis with high-risk human papillomavirus infection","volume":"7","author":"Xue","year":"2018","journal-title":"Cancer Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e7804","DOI":"10.7717\/peerj.7804","article-title":"Correlation between subsets of tumor-infiltrating immune cells and risk stratification in patients with cervical cancer","volume":"7","author":"Chen","year":"2019","journal-title":"PeerJ"},{"key":"B45","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12905-020-00972-0","article-title":"The disease stage-associated imbalance of th1\/th2 and th17\/treg in uterine cervical cancer patients and their recovery with the reduction of tumor burden","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Womens Health"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.07.106","article-title":"Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy","volume":"159","author":"Ohno","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.23812\/j.biol.regul.homeost.agents.20233707.348","article-title":"Comparison of lymphocyte subsets, inflammatory factors and postoperative infection in cervical cancer at stage I and stage II","volume":"37","author":"Wang","year":"2023","journal-title":"J Biol Regulators Homeostatic Agents"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0795-1","article-title":"Prediction of local recurrence in cervical cancer by a cox model comprised of lymph node status, lymph-vascular space invasion, and intratumoral th17 cell-infiltration","volume":"31","author":"Yu","year":"2014","journal-title":"Med Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e984539","DOI":"10.4161\/2162402X.2014.984539","article-title":"Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer","volume":"4","author":"Punt","year":"2015","journal-title":"OncoImmunology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/srep15179","article-title":"Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: A systematic review and meta-analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.105084","article-title":"Prognostic impact of regulatory T cell in head and neck squamous cell carcinoma: A systematic review and meta-analysis","volume":"112","author":"Cho","year":"2021","journal-title":"Oral Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.7150\/jca.42472","article-title":"The proportion and prognostic significance of T-regulatory cells in patients with gynecological cancers: A systematic review and meta-analysis","volume":"11","author":"Hu","year":"2020","journal-title":"J Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.174","article-title":"Human FOXP3 and cancer","volume":"29","author":"Martin","year":"2010","journal-title":"Oncogene"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1953","article-title":"Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies","volume":"15","author":"Pellegrini","year":"2009","journal-title":"Nat Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1442103\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T04:10:32Z","timestamp":1726027832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1442103\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":55,"alternative-id":["10.3389\/fonc.2024.1442103"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1442103","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"article-number":"1442103"}}